| Literature DB >> 30559468 |
Haiying Peng1, Dengtao Liu1, Yuhua Ma1, Wei Gao2.
Abstract
The transmission between community-associated (CA-) and healthcare-associated (HA-) methicillin-resistant Staphylococcus aureus (MRSA) has increased the challenge of infection control. To understand the clonal evolution and transmission of MRSA isolates, we compared the characteristics of 175 CA-MRSA and 660 HA-MRSA strains at a Chinese tertiary hospital in 2012-2017. Antibiotic susceptibility was performed on VITEK system, the genetic background of the isolates was characterized by SCCmec, spa, and MLST typing, while virulence determinants were screened using conventional PCR. Although more than 70% of the CA-MRSA isolates were erythromycin and clindamycin resistant, CA-MRSA was more susceptible than HA-MRSA to most of the antibiotics tested. ST239-MRSA-III-t030 (30%) was the most prevalent clone among HA-MRSA, while ST59-MRSA-IVa-t437 (28.8%) was the major clone among CA-MRSA. Notably, ST59-MRSA-IVa-t437 accounted for 6.7% of the chosen HA-MRSA isolates. Additionally, difference in virulence gene content was found between the CA- and HA-MRSA strains. In conclusion, epidemiological characteristics were largely different between CA- and HA-MRSA. Although ST239-MRSA-III-t030 is still the predominant clone among HA-MRSA, the community clone ST59-MRSA-IVa-t437 has the potential of becoming an essential part of HA-MRSA in the region tested.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30559468 PMCID: PMC6297250 DOI: 10.1038/s41598-018-36206-5
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Antimicrobial susceptibilities of HA-MRSA and CA-MRSA isolates.
| Antibiotic | CA-MRSA (n = 175) | HA-MRSA (n = 660) | |||||
|---|---|---|---|---|---|---|---|
| Rb, n (%) | Ic, n (%) | Sd, n (%) | Rb, n (%) | Ic, n (%) | Sd, n (%) | ||
| Penicillin | 175 (100.0) | 0 (0) | 0 (0) | 660 (100.0) | 0 (0) | 0 (0) | — |
| Oxacillin | 175 (100.0) | 0 (0) | 0 (0) | 660 (100.0) | 0 (0) | 0 (0) | — |
| Erythromycin | 137 (78.3) | 8 (4.6) | 30 (17.1) | 542 (82.1) | 16 (2.4) | 102 (15.5) | >0.05 |
| Ciprofloxacin | 10 (5.7) | 0 (0) | 165 (94.3) | 568 (86.1) | 0 (0) | 92 (13.9) | <0.01 |
| Tetracycline | 27 (15.4) | 2 (1.1) | 146 (82.4) | 541 (82.0) | 3 (0.5) | 116 (17.6) | <0.01 |
| Clindamycin | 155 (88.6) | 0 (0) | 20 (11.4) | 591 (89.5) | 14 (2.1) | 55 (8.3) | >0.05 |
| TMP/SMXa | 18 (10.3) | 0 (0) | 157 (89.7) | 401 (60.8) | 0 (0) | 259 (39.2) | <0.01 |
| Rifampicin | 6 (3.4) | 7 (4.0) | 162 (92.6) | 198 (30.0) | 9 (1.4) | 453 (68.6) | <0.01 |
| Gentamicin | 11 (6.3) | 0 (0) | 164 (93.7) | 433 (65.6) | 0 (0) | 227 (34.4) | <0.01 |
| Nitrofurantoin | 10 (5.7) | 6 (3.4) | 159 (90.9) | 119 (18.0) | 2 (0.3) | 539 (81.7) | <0.01 |
| Vancomycin | 0 (0) | 0 (0) | 175 (100.0) | 0 (0) | 0 (0) | 660 (100.0) | — |
| Levofloxacin | 51 (29.1) | 2 (1.1) | 122 (69.7) | 384 (58.2) | 0 (0) | 276 (41.8) | <0.01 |
| Linezolid | 0 (0) | 0 (0) | 175(100.0) | 0 (0) | 0 (0) | 660 (100.0) | — |
| Tigecycline | 0 (0) | 0 (0) | 175 (100.0) | 0 (0) | 0 (0) | 660 (100.0) | — |
| Quinupristin/Dalfopristin | 0 (0) | 1 (0.6) | 174 (99.4) | 0 (0) | 0 (0) | 660 (100.0) | — |
aTMP-SMX, trimethoprim/sulfamethoxazole. bR, Resistant. cI, Intermediate. dS, Susceptible. eThe resistance rates of antibiotics among CA-MRSA compared with those among HA-MRSA.
Molecular characteristics of chosen CA-MRSA isolates described in this study (n = 80).
| No. of isolates | Clonal complex (CC) | ST (n, %) | SCC | |
|---|---|---|---|---|
| 42 | CC59 | ST59 (37, 52.5) | t437 (34), t441 (2), t034 (1) | IVa (28), V (5), III (4) |
| ST338 (5, 6.25) | t437 (4), t441(1) | IVa (4), III (1) | ||
| 10 | CC1 | ST1 (6, 7.5) | t127(6) | IVa (4), III (2) |
| ST188 (4, 5.0) | t2310 (2), t189 (1), t12147 (1) | IVa (4) | ||
| 7 | CC5 | ST5 (3, 3.75) | t002 (3) | IVa (2), N (1) |
| ST1507(2, 2.5) | t664 (2) | V (2) | ||
| ST149 (2, 2.5) | t437 (2) | III (1), IVa (1) | ||
| 6 | CC398 | ST398 (6, 7.5) | t034 (5), t011 (1) | IVa (6) |
| 5 | CC88 | ST88 (5, 6.25) | t2310 (2), t7637 (2), t15796 (1) | IVa (3), V (1), N (1) |
| 5 | CC239 | ST239 (5, 6.25) | t030 (5) | III (4), IVa (1) |
| 3 | CC22 | ST22 (2, 2.5) | t5983 (2) | IVa (2) |
| ST217 (1, 1.25) | t309 (1) | III (1) | ||
| 1 | CC121 | ST121 (1, 1.25) | t159 (1) | IVa (1) |
| 1 | CC9 | ST9 (1, 1.25) | t309 (1) | V (1) |
Molecular characteristics of HA-MRSA isolates described in this study (n = 120).
| No. of isolates | Clonal complex (CC) | ST (n, %) | SCC | |
|---|---|---|---|---|
| 74 | CC239 | ST239 (74, 61.7) | t030 (56), t037(14), t632(3), t7576 (1) | III (56), II (18) |
| 24 | CC5 | ST5 (20, 16.7) | t002 (14), t570 (3), t187 (2), t2460 (1) | II (18), III (1), N (1) |
| ST2590 (1, 0.8) | t002 (1) | II (1) | ||
| ST105 (3, 2.5) | t688 (3) | II (3) | ||
| 12 | CC59 | ST59 (12, 10.0) | t437 (11), t1451 (1) | IVa (8), III (4) |
| 4 | CC398 | ST398 (4, 3.3) | t034 (4) | III (2), II (2) |
| 2 | CC30 | ST1777 (1, 0.8) | t3651 (1) | II (1) |
| ST30 (1, 0.8) | t019 (1) | IVa (1) | ||
| 1 | CC88 | ST88 (1, 0.8) | t7637 (1) | I (1) |
| 1 | CC1 | ST1 (1, 0.8) | t114 (1) | III (1) |
| 1 | CC45 | ST45 (1, 0.8) | t2637 (1) | IVa (1) |
| 1 | CC7 | ST7 (1, 0.8) | t091 (1) | IVa (1) |
Virulence gene distribution among the five specific molecular types of MRSA isolates.
| Isolates (n) | hla (%) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ST239-MRSA-III-t030 (HA-MRSA) | 36 | 100 | 100 | 100 | 94.4 | 55.6 | 77.8 | 100 | 66.7 | 0 | 33.3 | 0 | 0 | 0 | 0 | 0 | 0 | 5.6 | 0 | 5.6 | 0 | 91.7 | 0 | 0 |
| ST5-MRSA-II-t002 (HA-MRSA) | 12 | 100 | 100 | 100 | 100 | 83.3 | 100 | 100 | 41.7 | 58.3 | 25 | 0 | 33.3 | 0 | 0 | 91.7 | 8.3 | 75 | 41.7 | 0 | 0 | 75 | 0 | 0 |
| ST239-MRSA-III-t037 (HA-MRSA) | 14 | 100 | 100 | 100 | 100 | 50 | 100 | 100 | 50 | 0 | 28.6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 50 | 0 | 100 | 0 | 0 |
| ST59-MRSA-IVa-t437 (HA-MRSA) | 8 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 12.5 | 87.5 | 0 | 0 | 0 | 0 | 0 | 12.5 | 100 | 0 | 100 | 100 | 0 | 0 |
| ST59-MRSA-IVa-t437 (CA-MRSA) | 23 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 87 | 0 | 0 | 95.7 | 0 | 0 | 0 | 8.7 | 4.3 | 0 | 91.3 | 78.3 | 82.6 | 100 | 0 | 21.7 |
Antimicrobial resistance profiles among the five specific molecular types of MRSA isolates.
| ST239-MRSA-III-t030 (HA, n = 36) | ST5-MRSA-II-t002 (HA, n = 12) | ST239-MRSA-III-t037 (HA, n = 14) | ST59-MRSA-IVa-t437 (HA, n = 8) | ST59-MRSA-IVa-t437 (CA, n = 23) | |
|---|---|---|---|---|---|
| Penicillin (%) | 100 | 100 | 100 | 100 | 100 |
| Oxacillin (%) | 100 | 100 | 100 | 100 | 100 |
| Erythromycin (%) | 72.2 | 58.3 | 78.6 | 100 | 82.6 |
| Ciprofloxacin (%) | 94.4 | 41.7 | 78.6 | 0 | 0 |
| Tetracycline (%) | 94.4 | 58.3 | 71.4 | 12.5 | 13.0 |
| Clindamycin (%) | 91.7 | 91.7 | 64.3 | 25 | 78.3 |
| TMP/SMX (%) | 41.7 | 33.3 | 64.3 | 25 | 0 |
| Rifampicin (%) | 22.2 | 16.7 | 7.1 | 0 | 0 |
| Gentamicin (%) | 94.4 | 66.7 | 50 | 25 | 0 |
| Nitrofurantoin (%) | 8.3 | 0 | 21.4 | 0 | 0 |
| Vancomycin (%) | 0 | 0 | 0 | 0 | 0 |
| Levofloxacin (%) | 52.8 | 41.7 | 85.7 | 0.0 | 21.7 |
| Linezolid (%) | 0 | 0 | 0 | 0 | 0 |
| Tigecycline (%) | 0 | 0 | 0 | 0 | 0 |
| Quinupristin/ Dalfopristin (%) | 0 | 0 | 0 | 0 | 0 |
Distribution of toxin genes in CA- and HA-MRSA strains.
| Virulence factor | CA-MRSA (n = 175) | HA-MRSA (n = 660) | |
|---|---|---|---|
| n (%) | n (%) | ||
|
| |||
|
| 162 (92.6) | 619 (93.8) | >0.05 |
|
| 162 (92.6) | 626 (94.8) | >0.05 |
|
| 138 (78.9) | 601(91.1) | <0.01 |
|
| 127 (72.6) | 655 (99.2) | <0.01 |
|
| 143 (81.7) | 361 (54.7) | <0.01 |
|
| 142 (81.1) | 479 (72.6) | <0.05 |
|
| |||
|
| 171 (97.7) | 655 (99.2) | >0.05 |
|
| 114 (65.1) | 467 (70.8) | >0.05 |
|
| |||
|
| 1 (0.6) | 174 (26.4) | <0.01 |
|
| 13 (7.4) | 51 (7.7) | >0.05 |
|
| 84 (48.0) | 57 (8.6) | <0.01 |
|
| 5 (2.9) | 60 (9.1) | <0.01 |
|
| 0 | 0 | — |
|
| 0 | 0 | — |
|
| 5 (2.9) | 29 (4.4) | >0.05 |
|
| 1 (0.6) | 1 (0.2) | >0.05 |
|
| 24 (13.7) | 54 (8.2) | <0.05 |
|
| 39 (22.3) | 32 (4.8) | <0.01 |
|
| 33 (18.9) | 9 (1.4) | <0.01 |
|
| |||
|
| 93 (53.1) | 78 (11.8) | <0.01 |
|
| 123 (70.3) | 482 (73.0) | >0.05 |
|
| 0 | 0 | — |
|
| 7 (4.0) | 17 (2.6) | >0.05 |
icaA: intercellular adhesion gene A, icaD: intercellular adhesion gene D, clfA: clumping factor A gene, clfB: clumping factor A gene, fnbA: fibronectin-binding protein A gene, fnbB: fibronectin-binding protein B gene, hla: alpha- haemolysin gene, hld: delta-haemolysin gene, tst: toxic shock syndrome toxin -1 gene, sea~see, seg~sei, sek, seq: the genes of staphylococcal enterotoxins (SEs), lukSF-PV: genes encoding Panton-Valentine Leukocidin S and F subunit, PSMα: phenol-soluble modulin α gene, eta: exfoliative toxin A gene, etb: exfoliative toxin B gene.